Capital Research Global Investors Sells 5,219 Shares of Encompass Health Corporation $EHC

Capital Research Global Investors lowered its holdings in Encompass Health Corporation (NYSE:EHC) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 597,302 shares of the company’s stock after selling 5,219 shares during the period. Capital Research Global Investors owned approximately 0.59% of Encompass Health worth $63,398,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Assetmark Inc. grew its stake in Encompass Health by 88.1% during the third quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after acquiring an additional 140 shares in the last quarter. WPG Advisers LLC grew its stake in Encompass Health by 73.3% during the fourth quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after acquiring an additional 137 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Encompass Health during the fourth quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd grew its stake in Encompass Health by 36,200.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after acquiring an additional 362 shares in the last quarter. Finally, Covestor Ltd grew its stake in Encompass Health by 24.4% during the fourth quarter. Covestor Ltd now owns 540 shares of the company’s stock valued at $57,000 after acquiring an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the transaction, the executive vice president owned 24,755 shares of the company’s stock, valued at $2,588,382.80. The trade was a 2.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Leerink Partners set a $152.00 price objective on shares of Encompass Health in a research note on Friday, May 22nd. TD Cowen assumed coverage on shares of Encompass Health in a research note on Thursday, May 28th. They set a “buy” rating and a $125.00 price objective for the company. Finally, Barclays reduced their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $143.86.

Encompass Health Price Performance

EHC stock opened at $104.38 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99. The stock has a market cap of $10.35 billion, a PE ratio of 17.43, a P/E/G ratio of 2.20 and a beta of 0.72. The firm has a 50 day simple moving average of $103.99 and a two-hundred day simple moving average of $104.82.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the company earned $1.37 EPS. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, analysts predict that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s payout ratio is currently 12.69%.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.